- Home
- MKZR vs KZIA Comparison
MKZR vs KZIA Comparison
Compare MKZR & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MKZR
- KZIA
- Stock Information
- Founded
- MKZR 2012
- KZIA 1994
- Country
- MKZR United States
- KZIA Australia
- Employees
- MKZR N/A
- KZIA N/A
- Industry
- MKZR
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- MKZR
- KZIA Health Care
- Exchange
- MKZR Nasdaq
- KZIA Nasdaq
- Market Cap
- MKZR 10.3M
- KZIA 11.7M
- IPO Year
- MKZR N/A
- KZIA 1999
- Fundamental
- Price
- MKZR $5.14
- KZIA $7.25
- Analyst Decision
- MKZR
- KZIA Strong Buy
- Analyst Count
- MKZR 0
- KZIA 3
- Target Price
- MKZR N/A
- KZIA $16.00
- AVG Volume (30 Days)
- MKZR 32.8K
- KZIA 236.0K
- Earning Date
- MKZR 11-11-2025
- KZIA 11-14-2025
- Dividend Yield
- MKZR 19.45%
- KZIA N/A
- EPS Growth
- MKZR N/A
- KZIA N/A
- EPS
- MKZR N/A
- KZIA N/A
- Revenue
- MKZR $21,294,932.00
- KZIA $1,549,158.00
- Revenue This Year
- MKZR N/A
- KZIA N/A
- Revenue Next Year
- MKZR N/A
- KZIA N/A
- P/E Ratio
- MKZR N/A
- KZIA N/A
- Revenue Growth
- MKZR 21.25
- KZIA 248983.08
- 52 Week Low
- MKZR $3.89
- KZIA $2.86
- 52 Week High
- MKZR $55.00
- KZIA $39.05
- Technical
- Relative Strength Index (RSI)
- MKZR 47.64
- KZIA 51.06
- Support Level
- MKZR $4.84
- KZIA $6.51
- Resistance Level
- MKZR $5.63
- KZIA $7.39
- Average True Range (ATR)
- MKZR 0.41
- KZIA 0.41
- MACD
- MKZR -0.04
- KZIA 0.05
- Stochastic Oscillator
- MKZR 35.16
- KZIA 78.14
About MKZR MacKenzie Realty Capital Inc.
Mackenzie Realty Capital Inc is a company which is a Real estate investment trust (REIT). The company has one reportable segment, income-producing real estate properties which consists of activities related to investing in real estate.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.